Fulminant hepatic failure associated with etodolac use.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 7717333.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Etodolac is a new pyranocarboxylic acid nonsteroidal anti-inflammatory agent with a unique chemical structure indicated for use in patients with painful musculoskeletal disorders and rheumatoid disease. Hepatotoxicity, in the form of reversible elevations in transaminases or bilirubin, occurs rarely. We present the first reported case of fulminant hepatic failure related to etodolac.
Medical subject headings
- Etodolac
- Hepatic Encephalopathy